Form 4: Arcutis Biotherapeutics Director Patrick J. Heron Reports Stock Purchase

Director Patrick J. Heron reports purchasing 6,300 shares of Arcutis Biotherapeutics at an average price of $13.6018 on May 9, 2025.

Summary

• On May 9, 2025, Patrick J. Heron, a director of Arcutis Biotherapeutics, Inc., purchased 6,300 shares of common stock at a weighted average price of $13.6018.
• The purchase was made in multiple transactions with prices ranging from $13.1504 to $13.9266.
• Following the reported transaction, Heron directly owns 18,826 shares and indirectly owns shares through various entities including Frazier Life Sciences X, L.P. (6,300 shares), Frazier Life Sciences VIII, L.P. (8,785,284 shares), FHM Life Sciences VIII, L.L.C. (7 shares), and The Heron Living Trust 11/30/2004 (23,688 shares).
• Heron disclaims beneficial ownership of shares held by Frazier Life Sciences X, L.P., Frazier Life Sciences VIII, L.P., and FHM Life Sciences VIII, L.L.C. except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The purchase itself could be seen as slightly positive, but the filing is primarily informational.

Positives

• The director's purchase could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The stock purchase by a director could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Arcutis Biotherapeutics, Director, Stock Purchase, Form 4, Beneficial Ownership, Heron, ARQT